Community post

The FDA has authorized Armata Pharmaceuticals to initiate a phase 1b/2a clinical trial, which they are calling "SWARM-P.a.", to test AP-PA02, its lead phage cocktail candidate, against Pseudomonas aeruginosa airway infections in cystic fibrosis patients. The trial should begin by the end of 2020.